Humanigen Forum: Community User: Rothschild123

Das ist ne Pille für “zu Hause”. Humanigen aber für schon hospitalisierten . Diese Kombi könnte die Pandemie endlich beenden, falls beine zugelassen werden 👍

Oct 1 (Reuters) - An antiviral pill developed by U.S. drugmaker Merck & Co (MRK.N) could half the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, with experts hailing it as a potential breakthrough in how the virus is treated. If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19. Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide.

Jetzt ist mir klar, warum die FDA Himanigen erstmal abgelehnt hat… Merck publizierte heute Phase 3 Ergebnisse des antiviralen Covid Medikaments… und US Regierung hat schon 1.7 Mln davon bestellt 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️

MHRA muss sich ja bald äußern

Alle geplante Module wurden MHRA eingereicht. Wurde betont, dass hospitalisierungszahlen in UK steigen und dass MHRA bzw UK ein Leader der Welt in Medikation insbesondere für Covid 19 ist

Kann mir einer kurz sagen was die neue Info ist ? Positiv oder negativ ? 😁 My Englisch is Not so Good ;)

Unglaublich was die Börse heute macht

🦾

We are pleased with the engagement with MHRA and are committed to continue to work with the agency as necessary to enable MHRA to review our application. As the United Kingdom’s Health Secretary recently stated, the UK is leading the world in identifying and rolling out life-saving medicines, particularly for COVID-19,”1 said Cameron Durrant, CEO of Humanigen. “A UK study funded by the Medical Research Council demonstrated benefits of GM-CSF neutralization in hospitalized COVID-19 patients and we believe results of our LIVE-AIR Phase 3 trial of lenzilumab provide further evidence for the benefits of this approach. Thus, we are seeking Conditional Marketing Authorization with a view to bringing lenzilumab to patients in the UK. We note in the UK there have been more than 20,000 new hospitalizations in the month of September and as of September 27th there were 7,007 people currently hospitalized for COVID-19.”2,3

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced it has submitted all the planned modules as well as a risk management plan and pediatric investigation plan for the lenzilumab Conditional Marketing Authorization (CMA) in hospitalized COVID-19 patients to the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). MHRA has previously accepted the application for expedited COVID-19 rolling review.

Wie Bombe 🤣

Jeder Zeit

Da muss doch bald was gehen 😅

Alles bekannt, aber poste es hier trotzdem

https://www.natap.org/2021/IDWeek/IDWeek_04.htm

Wir lassen uns mal überraschen 🤷‍♂️